SITC_Friday_2017_Khaaliq_Thomas-21.jpgThe SITC 2017 Microlearning Clinical Trials - Novel Combinations Series has been developed with content from abstract and faculty presentations conducted at the Society for Immunotherapy of Cancer 32nd Annual Meeting (SITC 2017). The microlearning series provide a quick, easily accessible format for clinicians and researchers to learn about the latest advances in cancer immunotherapy from experts in the field.
 

The Clinical Trials - Novel Combinations series has three modules.

 

 

Module 1: Early FDG-PET Response Correlates with Dose and Efficacy in Patients with Microsatellite Stable mCRC Treated with Carcinoembryonic Antigen T-cell Bispecific (CEA-TCB) Antibody Plus Atezolizumab

Jose Saro, MD - Roche Innovation Center Zurich


Module 2: First-in-Human Phase 1 Dose Escalation and Expansion of a Novel Combination, Anti–CSF-1 Receptor (Cabiralizumab) Plus Anti–PD-1 (Nivolumab), in Patients with Advanced Solid Tumors

Zev Wainberg, MD - UCLA School of Medicine


Module 3: DNA Vaccine with PD-1 Blockade Elicits Anti-Tumor Responses in Patients with Metastatic, Castration-Resistant Prostate Cancer (mCRPC)

Douglas McNeel, MD, PhD - University of Wisconsin

 

 

Target Audience

These modules have been designed to meet the educational needs of researchers and healthcare professionals involved in cancer research and clinical care.

 

Course Available Beginning: August 16, 2018

 

 

Course Objectives
Upon completion of this activity, participants will be able to:
  • Define novel immunotherapy combinations being tested in pre-clinical and clinical settings.
  • Describe the mechanism of action of novel IO agents in combinatorial strategies.
  • Explain how novel therapies work in combination with PD-1/PD-L1 blockade.
Register Now
In order to access this program after registering, a SITC account will be provided for you based on the information you have entered.

To access your account after your purchase, use the My Account links on the left hand side of this page to login using the information your provide here.
According to our records there is already a SITC account using the email address you have provided.

To continue with your registration please enter your account password. If you do not know your account password you can retrieve it here: Forgot Password?
First Name:
Last Name:
Email:
Confirm Email:
Which degree best describes you? :
Other degree, please describe:
What is your professional role? (If more than one applies to you, type additional roles below):
Other professional role, please describe:
If more than one professional role applies to you, please enter the additional roles here:
Which of the following best describes your primary work setting? :
Other primary work setting, please describe: :
What is your area of specialization?:
Other area of specialization, please describe::
Product:
SITC 2017 Microlearning: Clinical Trials: Novel Combinations Series
The email address you have entered has an existing SITC account.

Please enter your password in the field below. Forgot Password?

Email:
Password:
Country:
Billing Address:
City:
State:
State/Province:
Zip:
Expiration: 
Pre-Test: Module 1

Before beginning the presentation, please complete the brief pre-test questions.

Module 1: Early FDG-PET Response Correlates with Dose and Efficacy in Patients with Microsatellite Stable mCRC Treated with Carcinoembryonic Antigen T-cell Bispecific (CEA-TCB) Antibody Plus Atezolizumab

The SITC 2017 Microlearning: Clinical Trials - Novel Combinations Series has been developed with content from abstract and faculty presentations conducted at the Society for Immunotherapy of Cancer 32nd Annual Meeting (SITC 2017)This is the first of three modules in the SITC 2017 Microlearning: Clinical Trials -  Novel Combinations Series.

Speaker Information
Jose Saro, MD  [ view bio ]
Pre-Test: Module 2

Before beginning the presentation, please complete the brief pre-test questions.

Module 2: First-in-Human Phase 1 Dose Escalation and Expansion of a Novel Combination, Anti–CSF-1 Receptor (Cabiralizumab) Plus Anti–PD-1 (Nivolumab), in Patients with Advanced Solid Tumors

The SITC 2017 Microlearning Clinical Trials - Novel Combinations Series has been developed with content from abstract and faculty presentations conducted at the Society for Immunotherapy of Cancer 32nd Annual Meeting (SITC 2017). This is the second of three modules in the SITC 2017 Microlearning: Clinical Trials - Novel Combinations Series.
 

 

Speaker Information
Zev Wainberg, MD  [ view bio ]
Pre-Test: Module 3

Before beginning the presentation, please complete the brief pre-test questions.

Module 3: DNA Vaccine with PD-1 Blockade Elicits Anti-Tumor Responses in Patients with Metastatic, Castration-Resistant Prostate Cancer (mCRPC)

The SITC 2017 Microlearning: Clinical Trials - Novel Combinations Series has been developed with content from abstract and faculty presentations conducted at the Society for Immunotherapy of Cancer 32nd Annual Meeting (SITC 2017). This is the final of three modules in the SITC 2017 Microlearning: Clinical Trials - Novel Combinations Series.

Speaker Information
Douglas McNeel, MD, PhD  [ view bio ]
Individual topic purchase: Selected